Brickell Biotech Inc
F:VCC2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Haidilao International Holding Ltd
HKEX:6862
|
CN |
|
C
|
Centenial Surgical Suture Ltd
BSE:531380
|
IN |
|
N
|
Ningbo Henghe Precision Industry Co Ltd
SZSE:300539
|
CN |
|
T
|
Trio Industrial Electronics Group Ltd
HKEX:1710
|
HK |
|
G
|
Giant Group Ltd
OTC:GGLT
|
US |
|
Vienna Insurance Group AG Wiener Versicherung Gruppe
OTC:VNRGF
|
AT |
|
P
|
Pebble Beach Systems Group PLC
LSE:PEB
|
UK |
|
Cool Link (Holdings) Ltd
HKEX:8491
|
SG |
|
Housing and Urban Development Corporation Ltd
NSE:HUDCO
|
IN |
|
B
|
Boqii Holding Ltd
AMEX:BQ
|
CN |
|
Naigai Co Ltd
TSE:8013
|
JP |
|
Nokia Oyj
OMXH:NOKIA
|
FI |
|
Z
|
Zibuyu Group Ltd
HKEX:2420
|
CN |
|
PKSHA Technology Inc
TSE:3993
|
JP |
|
M
|
Modern Healthcare Technology Holdings Ltd
HKEX:919
|
HK |
|
InnoCare Pharma Ltd
SSE:688428
|
CN |
|
S
|
Silk Road Logistics Holdings Ltd
HKEX:988
|
HK |
|
PTC Industries Ltd
BSE:539006
|
IN |
|
Indo Us Bio-Tech Ltd
BSE:541304
|
IN |
|
T
|
TScan Therapeutics Inc
NASDAQ:TCRX
|
US |
|
C
|
Cubex Tubings Ltd
NSE:CUBEXTUB
|
IN |
Brickell Biotech Inc
Total Current Assets
Brickell Biotech Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Brickell Biotech Inc
F:VCC2
|
Total Current Assets
$10.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$29.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$18B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
Brickell Biotech Inc
Glance View
Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 16 full-time employees. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.
See Also
What is Brickell Biotech Inc's Total Current Assets?
Total Current Assets
10.1m
USD
Based on the financial report for Dec 31, 2022, Brickell Biotech Inc's Total Current Assets amounts to 10.1m USD.
What is Brickell Biotech Inc's Total Current Assets growth rate?
Total Current Assets CAGR 1Y
-66%
Over the last year, the Total Current Assets growth was -66%.
